patient_id stringlengths 12 12 | record_id stringlengths 11 11 | cancer_type stringclasses 1
value | histology stringclasses 3
values | stage_at_diagnosis stringclasses 3
values | driver_mutation stringclasses 7
values | pd_l1_tps_percent int64 5 41 | tmb_mutations_per_mb float64 1.5 25 | age_at_diagnosis int64 38 90 | sex stringclasses 2
values | ecog_performance_status int64 0 4 | smoking_pack_years int64 0 111 | primary_tumor_size_cm float64 2 10 | metastatic_sites_count int64 0 11 | first_line_regimen stringclasses 6
values | overall_survival_months float64 4 83 | censored bool 2
classes | msi_status stringclasses 2
values | record_generation_timestamp stringdate 2026-03-15 05:35:56 2026-03-15 05:36:02 | synthetic_source stringclasses 1
value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ANODE_772617 | REC_0003801 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 29 | 10.2 | 82 | female | 2 | 12 | 7.2 | 4 | pembrolizumab 200 mg q3w | 16.8 | false | MSS | 2026-03-15T05:35:57.785271+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_777083 | REC_0003802 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 24 | 10.6 | 77 | female | 2 | 11 | 5.2 | 2 | alectinib 600 mg BID | 9.1 | false | MSS | 2026-03-15T05:35:57.785506+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_680469 | REC_0003803 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 14 | 13 | 66 | female | 1 | 12 | 4.7 | 6 | entrectinib 600 mg daily | 11.2 | false | MSI-H | 2026-03-15T05:35:57.785745+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_885188 | REC_0003804 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 29 | 12.5 | 67 | female | 1 | 14 | 6.2 | 1 | alectinib 600 mg BID | 10.3 | false | MSI-H | 2026-03-15T05:35:57.785984+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_907180 | REC_0003805 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 25 | 9.7 | 64 | female | 0 | 15 | 6.4 | 5 | osimertinib 80 mg daily | 14.9 | true | MSS | 2026-03-15T05:35:57.786219+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_321125 | REC_0003806 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 21 | 17.6 | 76 | female | 3 | 8 | 3.5 | 7 | pembrolizumab 200 mg q3w | 7.9 | false | MSS | 2026-03-15T05:35:57.786453+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_833316 | REC_0003807 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 18 | 10.9 | 61 | female | 1 | 8 | 7.3 | 1 | osimertinib 80 mg daily | 11.3 | true | MSI-H | 2026-03-15T05:35:57.786691+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_406456 | REC_0003808 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 30 | 7.4 | 59 | female | 0 | 26 | 3.8 | 6 | carboplatin + paclitaxel + pembrolizumab | 9.9 | false | MSS | 2026-03-15T05:35:57.786925+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_958654 | REC_0003809 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 21 | 10 | 76 | female | 1 | 16 | 5.6 | 4 | osimertinib 80 mg daily | 10.9 | true | MSI-H | 2026-03-15T05:35:57.787158+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_216749 | REC_0003810 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 25 | 7.5 | 60 | female | 0 | 51 | 6.9 | 2 | carboplatin + paclitaxel + pembrolizumab | 21.1 | false | MSS | 2026-03-15T05:35:57.787463+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_697481 | REC_0003811 | Non-small cell lung cancer | Squamous cell carcinoma | III | None (PD-L1 high) | 28 | 2.9 | 62 | female | 0 | 38 | 7.1 | 0 | pembrolizumab 200 mg q3w | 53.2 | false | MSS | 2026-03-15T05:35:57.787713+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_157411 | REC_0003812 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 25 | 6.5 | 71 | female | 2 | 14 | 5.2 | 1 | osimertinib 80 mg daily | 13.4 | false | MSS | 2026-03-15T05:35:57.787949+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_695750 | REC_0003813 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 24 | 8.7 | 67 | female | 1 | 6 | 5.8 | 5 | osimertinib 80 mg daily | 14.2 | false | MSS | 2026-03-15T05:35:57.788233+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_703795 | REC_0003814 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 23 | 16.8 | 64 | female | 1 | 8 | 5.2 | 7 | sotorasib 960 mg daily | 13.9 | false | MSI-H | 2026-03-15T05:35:57.788478+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_534021 | REC_0003815 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 26 | 17.3 | 71 | male | 2 | 25 | 5.5 | 5 | entrectinib 600 mg daily | 8.7 | false | MSS | 2026-03-15T05:35:57.788723+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_326993 | REC_0003816 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 28 | 15.2 | 79 | female | 1 | 11 | 6.4 | 1 | osimertinib 80 mg daily | 28.4 | false | MSS | 2026-03-15T05:35:57.788957+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_694809 | REC_0003817 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 31 | 5.5 | 58 | female | 0 | 40 | 4.1 | 4 | pembrolizumab 200 mg q3w | 5.2 | false | MSS | 2026-03-15T05:35:57.789190+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_678258 | REC_0003818 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 31 | 21.3 | 68 | female | 1 | 17 | 4.7 | 2 | entrectinib 600 mg daily | 5.8 | false | MSI-H | 2026-03-15T05:35:57.789425+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_339073 | REC_0003819 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 26 | 7.4 | 74 | female | 1 | 21 | 5.5 | 3 | osimertinib 80 mg daily | 6.8 | false | MSS | 2026-03-15T05:35:57.789660+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_114342 | REC_0003820 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 25 | 7.5 | 63 | female | 0 | 15 | 4 | 1 | alectinib 600 mg BID | 13.6 | false | MSS | 2026-03-15T05:35:57.789889+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_325914 | REC_0003821 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 17 | 2.4 | 75 | male | 2 | 15 | 3.5 | 6 | osimertinib 80 mg daily | 15.9 | false | MSS | 2026-03-15T05:35:57.790123+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_808018 | REC_0003822 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 27 | 6.5 | 73 | female | 2 | 55 | 7.8 | 5 | carboplatin + paclitaxel + pembrolizumab | 23.9 | true | MSS | 2026-03-15T05:35:57.790350+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_227149 | REC_0003823 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 16 | 13.9 | 64 | female | 1 | 7 | 5.6 | 7 | osimertinib 80 mg daily | 9.5 | false | MSI-H | 2026-03-15T05:35:57.790645+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_589388 | REC_0003824 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 27 | 7.4 | 66 | male | 1 | 18 | 5.8 | 6 | entrectinib 600 mg daily | 14.9 | false | MSS | 2026-03-15T05:35:57.790881+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_944115 | REC_0003825 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 25 | 11.6 | 61 | female | 1 | 11 | 4.1 | 7 | osimertinib 80 mg daily | 10.9 | false | MSI-H | 2026-03-15T05:35:57.791117+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_517405 | REC_0003826 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 21 | 14 | 61 | male | 1 | 17 | 4.3 | 1 | osimertinib 80 mg daily | 21 | true | MSS | 2026-03-15T05:35:57.791352+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_997977 | REC_0003827 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 32 | 3.4 | 54 | female | 0 | 40 | 3.7 | 6 | carboplatin + paclitaxel + pembrolizumab | 5.8 | true | MSS | 2026-03-15T05:35:57.791581+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_305231 | REC_0003828 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 30 | 5 | 62 | female | 0 | 66 | 4.9 | 1 | carboplatin + paclitaxel + pembrolizumab | 14 | false | MSS | 2026-03-15T05:35:57.791813+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_901180 | REC_0003829 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 28 | 5.9 | 79 | female | 0 | 14 | 7 | 1 | osimertinib 80 mg daily | 33.6 | true | MSS | 2026-03-15T05:35:57.792042+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_445969 | REC_0003830 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 31 | 14.3 | 64 | female | 1 | 6 | 4.9 | 0 | osimertinib 80 mg daily | 7.4 | true | MSS | 2026-03-15T05:35:57.792310+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_771749 | REC_0003831 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 29 | 9.7 | 80 | female | 1 | 21 | 4.6 | 1 | entrectinib 600 mg daily | 33.5 | false | MSS | 2026-03-15T05:35:57.792541+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_109643 | REC_0003832 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 28 | 17.6 | 72 | female | 2 | 6 | 4.9 | 2 | entrectinib 600 mg daily | 11.7 | true | MSI-H | 2026-03-15T05:35:57.792775+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_146249 | REC_0003833 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 33 | 16.2 | 64 | male | 1 | 14 | 3.1 | 6 | osimertinib 80 mg daily | 8.9 | true | MSS | 2026-03-15T05:35:57.793013+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_483794 | REC_0003834 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 25 | 7.5 | 80 | female | 2 | 14 | 6.5 | 5 | osimertinib 80 mg daily | 8.6 | true | MSS | 2026-03-15T05:35:57.793243+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_759287 | REC_0003835 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 21 | 7.6 | 45 | male | 0 | 27 | 7.6 | 2 | pembrolizumab 200 mg q3w | 12.2 | false | MSS | 2026-03-15T05:35:57.793474+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_720097 | REC_0003836 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 27 | 11.8 | 75 | female | 2 | 12 | 6 | 3 | alectinib 600 mg BID | 7.4 | false | MSS | 2026-03-15T05:35:57.793764+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_303582 | REC_0003837 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 29 | 12 | 59 | female | 1 | 18 | 4.6 | 6 | osimertinib 80 mg daily | 9.9 | false | MSI-H | 2026-03-15T05:35:57.794004+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_957303 | REC_0003838 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 18 | 5 | 70 | female | 1 | 6 | 5.5 | 2 | alectinib 600 mg BID | 19.7 | false | MSS | 2026-03-15T05:35:57.794236+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_826345 | REC_0003839 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 27 | 18 | 64 | male | 1 | 21 | 4.6 | 5 | entrectinib 600 mg daily | 13.8 | true | MSI-H | 2026-03-15T05:35:57.794476+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_808424 | REC_0003840 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 24 | 7.6 | 68 | female | 1 | 26 | 7.7 | 2 | pembrolizumab 200 mg q3w | 23.7 | false | MSS | 2026-03-15T05:35:57.794705+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_442696 | REC_0003841 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 32 | 4.8 | 54 | female | 0 | 15 | 5.2 | 2 | carboplatin + paclitaxel + pembrolizumab | 12.5 | true | MSS | 2026-03-15T05:35:57.794940+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_208744 | REC_0003842 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 28 | 7 | 67 | female | 1 | 19 | 6.1 | 4 | osimertinib 80 mg daily | 12.5 | false | MSS | 2026-03-15T05:35:57.795168+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_649265 | REC_0003843 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 32 | 7.5 | 66 | female | 0 | 58 | 4 | 2 | carboplatin + paclitaxel + pembrolizumab | 11.8 | false | MSS | 2026-03-15T05:35:57.795397+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_465099 | REC_0003844 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 28 | 11.7 | 57 | male | 0 | 12 | 5.1 | 5 | entrectinib 600 mg daily | 11.2 | true | MSI-H | 2026-03-15T05:35:57.795632+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_550619 | REC_0003845 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 20 | 6.8 | 72 | male | 1 | 9 | 5.1 | 1 | osimertinib 80 mg daily | 19 | true | MSS | 2026-03-15T05:35:57.795867+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_837916 | REC_0003846 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 26 | 8.2 | 58 | female | 0 | 17 | 4.3 | 7 | entrectinib 600 mg daily | 16.2 | true | MSS | 2026-03-15T05:35:57.796192+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_778520 | REC_0003847 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 23 | 12 | 69 | male | 0 | 15 | 5.1 | 6 | osimertinib 80 mg daily | 13.1 | false | MSI-H | 2026-03-15T05:35:57.796450+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_142036 | REC_0003848 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 27 | 8.2 | 76 | female | 1 | 42 | 4 | 6 | pembrolizumab 200 mg q3w | 4 | false | MSS | 2026-03-15T05:35:57.796686+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_904207 | REC_0003849 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 23 | 13.8 | 76 | female | 0 | 18 | 4.8 | 8 | osimertinib 80 mg daily | 9.3 | true | MSI-H | 2026-03-15T05:35:57.796991+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_568091 | REC_0003850 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 25 | 12.5 | 64 | female | 1 | 3 | 5.8 | 2 | osimertinib 80 mg daily | 11.2 | true | MSI-H | 2026-03-15T05:35:57.797236+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_215705 | REC_0003851 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 19 | 11.1 | 75 | female | 1 | 14 | 4.2 | 0 | entrectinib 600 mg daily | 23.1 | true | MSS | 2026-03-15T05:35:57.797470+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_833390 | REC_0003852 | Non-small cell lung cancer | Adenocarcinoma | III | KRAS G12C | 20 | 15 | 55 | female | 1 | 12 | 3.6 | 0 | sotorasib 960 mg daily | 29.4 | false | MSI-H | 2026-03-15T05:35:57.797707+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_932821 | REC_0003853 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 28 | 10.2 | 72 | female | 2 | 19 | 8.5 | 0 | entrectinib 600 mg daily | 14.3 | true | MSI-H | 2026-03-15T05:35:57.797945+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_445262 | REC_0003854 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 31 | 6.5 | 65 | female | 1 | 6 | 3.6 | 4 | osimertinib 80 mg daily | 6.6 | true | MSS | 2026-03-15T05:35:57.798180+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_834401 | REC_0003855 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 20 | 12.9 | 58 | female | 0 | 15 | 6.3 | 4 | osimertinib 80 mg daily | 12.5 | true | MSI-H | 2026-03-15T05:35:57.798420+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_536190 | REC_0003856 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR exon 19 deletion | 28 | 6.9 | 70 | female | 1 | 4 | 4.5 | 0 | osimertinib 80 mg daily | 34.1 | true | MSS | 2026-03-15T05:35:57.798649+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_644330 | REC_0003857 | Non-small cell lung cancer | Adenocarcinoma | III | None (PD-L1 high) | 25 | 19.4 | 75 | female | 2 | 8 | 5.2 | 0 | pembrolizumab 200 mg q3w | 36.6 | false | MSS | 2026-03-15T05:35:57.798879+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_621710 | REC_0003858 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 28 | 4 | 74 | female | 1 | 13 | 6.1 | 1 | alectinib 600 mg BID | 17.4 | true | MSS | 2026-03-15T05:35:57.799114+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_282121 | REC_0003859 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR L858R | 29 | 18 | 68 | female | 1 | 15 | 5 | 0 | osimertinib 80 mg daily | 34 | true | MSI-H | 2026-03-15T05:35:57.799350+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_884646 | REC_0003860 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 24 | 15.4 | 72 | female | 3 | 30 | 5.9 | 1 | osimertinib 80 mg daily | 23.9 | true | MSS | 2026-03-15T05:35:57.799588+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_326525 | REC_0003861 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 23 | 14 | 60 | male | 1 | 12 | 4.1 | 6 | sotorasib 960 mg daily | 4 | true | MSS | 2026-03-15T05:35:57.799832+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_437944 | REC_0003862 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 20 | 10.3 | 66 | female | 1 | 7 | 5.6 | 3 | entrectinib 600 mg daily | 14.4 | true | MSI-H | 2026-03-15T05:35:57.800225+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_274217 | REC_0003863 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 23 | 14.3 | 65 | female | 1 | 13 | 6.4 | 1 | sotorasib 960 mg daily | 15.8 | true | MSS | 2026-03-15T05:35:57.800499+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_385658 | REC_0003864 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 24 | 15.6 | 58 | male | 0 | 8 | 5.2 | 2 | osimertinib 80 mg daily | 21.3 | true | MSS | 2026-03-15T05:35:57.800759+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_923929 | REC_0003865 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 23 | 18 | 69 | female | 1 | 11 | 4.7 | 6 | alectinib 600 mg BID | 5.8 | true | MSS | 2026-03-15T05:35:57.801011+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_608413 | REC_0003866 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 23 | 7.5 | 70 | female | 2 | 40 | 4.7 | 2 | carboplatin + paclitaxel + pembrolizumab | 17.7 | true | MSS | 2026-03-15T05:35:57.801264+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_536718 | REC_0003867 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 22 | 5.7 | 52 | male | 0 | 13 | 5 | 2 | osimertinib 80 mg daily | 21.5 | true | MSS | 2026-03-15T05:35:57.801530+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_454595 | REC_0003868 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 27 | 11 | 60 | male | 0 | 29 | 5.2 | 6 | osimertinib 80 mg daily | 9.3 | false | MSS | 2026-03-15T05:35:57.801779+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_899956 | REC_0003869 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 26 | 16 | 61 | male | 0 | 21 | 5 | 5 | alectinib 600 mg BID | 8.7 | true | MSS | 2026-03-15T05:35:57.802020+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_271830 | REC_0003870 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 26 | 2 | 53 | male | 0 | 2 | 6.1 | 2 | osimertinib 80 mg daily | 12.8 | true | MSS | 2026-03-15T05:35:57.802257+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_555193 | REC_0003871 | Non-small cell lung cancer | Large cell carcinoma | III | None (PD-L1 high) | 30 | 5.6 | 64 | female | 1 | 5 | 7.5 | 0 | pembrolizumab 200 mg q3w | 22.8 | false | MSS | 2026-03-15T05:35:57.802498+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_296407 | REC_0003872 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 23 | 12.5 | 73 | female | 2 | 17 | 6.5 | 6 | osimertinib 80 mg daily | 15.5 | true | MSS | 2026-03-15T05:35:57.802734+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_964255 | REC_0003873 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 21 | 13.7 | 61 | male | 1 | 12 | 6.2 | 6 | sotorasib 960 mg daily | 7.7 | true | MSI-H | 2026-03-15T05:35:57.802975+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_873975 | REC_0003874 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 21 | 9.1 | 60 | female | 1 | 60 | 6.1 | 1 | carboplatin + paclitaxel + pembrolizumab | 10.8 | true | MSS | 2026-03-15T05:35:57.803207+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_747946 | REC_0003875 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 27 | 14.3 | 58 | male | 1 | 21 | 2.5 | 5 | entrectinib 600 mg daily | 12.1 | true | MSI-H | 2026-03-15T05:35:57.803561+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_693256 | REC_0003876 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 29 | 14.5 | 71 | female | 2 | 15 | 6 | 4 | osimertinib 80 mg daily | 7.8 | false | MSS | 2026-03-15T05:35:57.803808+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_730555 | REC_0003877 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 26 | 6.8 | 66 | female | 0 | 42 | 2.2 | 7 | carboplatin + paclitaxel + pembrolizumab | 14 | true | MSS | 2026-03-15T05:35:57.804047+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_639841 | REC_0003878 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 17 | 6.4 | 50 | male | 0 | 46 | 5.2 | 2 | carboplatin + paclitaxel + pembrolizumab | 13.7 | true | MSS | 2026-03-15T05:35:57.804344+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_765297 | REC_0003879 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 23 | 10.7 | 63 | male | 0 | 25 | 4.5 | 4 | osimertinib 80 mg daily | 4 | false | MSS | 2026-03-15T05:35:57.804588+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_859280 | REC_0003880 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 25 | 10.8 | 62 | female | 0 | 20 | 5.6 | 7 | alectinib 600 mg BID | 15.3 | false | MSS | 2026-03-15T05:35:57.804825+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_784670 | REC_0003881 | Non-small cell lung cancer | Adenocarcinoma | III | None (PD-L1 high) | 22 | 9.7 | 65 | female | 0 | 10 | 5.9 | 0 | pembrolizumab 200 mg q3w | 24.6 | true | MSS | 2026-03-15T05:35:57.805059+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_778187 | REC_0003882 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 30 | 18.2 | 57 | female | 0 | 9 | 4.9 | 2 | osimertinib 80 mg daily | 17.4 | true | MSS | 2026-03-15T05:35:57.805296+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_581812 | REC_0003883 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 25 | 5.1 | 65 | female | 1 | 53 | 4.3 | 3 | carboplatin + paclitaxel + pembrolizumab | 11.8 | false | MSS | 2026-03-15T05:35:57.805527+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_716450 | REC_0003884 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 26 | 17.1 | 70 | female | 2 | 3 | 5.2 | 7 | entrectinib 600 mg daily | 7.7 | false | MSS | 2026-03-15T05:35:57.805762+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_894779 | REC_0003885 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 30 | 11.2 | 69 | female | 0 | 5 | 4.3 | 4 | osimertinib 80 mg daily | 7.7 | true | MSI-H | 2026-03-15T05:35:57.805996+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_139549 | REC_0003886 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 34 | 4.3 | 59 | female | 0 | 1 | 5 | 6 | carboplatin + paclitaxel + pembrolizumab | 7.2 | true | MSS | 2026-03-15T05:35:57.806228+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_258787 | REC_0003887 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 24 | 4.6 | 63 | female | 0 | 10 | 5.2 | 2 | sotorasib 960 mg daily | 6.7 | false | MSS | 2026-03-15T05:35:57.806460+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_729788 | REC_0003888 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 20 | 17 | 79 | male | 2 | 13 | 3.7 | 6 | osimertinib 80 mg daily | 11.8 | true | MSI-H | 2026-03-15T05:35:57.806748+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_961533 | REC_0003889 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 24 | 4.9 | 69 | female | 0 | 45 | 5.5 | 5 | carboplatin + paclitaxel + pembrolizumab | 12.9 | false | MSS | 2026-03-15T05:35:57.806982+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_880310 | REC_0003890 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 25 | 7.9 | 66 | female | 0 | 37 | 6.3 | 8 | carboplatin + paclitaxel + pembrolizumab | 6.7 | true | MSS | 2026-03-15T05:35:57.807211+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_471935 | REC_0003891 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 28 | 9.6 | 69 | male | 0 | 29 | 5.1 | 1 | pembrolizumab 200 mg q3w | 23.8 | false | MSS | 2026-03-15T05:35:57.807444+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_318437 | REC_0003892 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 24 | 15.5 | 73 | female | 0 | 19 | 6.5 | 2 | alectinib 600 mg BID | 15.9 | false | MSS | 2026-03-15T05:35:57.807675+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_405618 | REC_0003893 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 22 | 9.6 | 66 | female | 0 | 28 | 6.6 | 6 | entrectinib 600 mg daily | 8.5 | true | MSS | 2026-03-15T05:35:57.807902+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_720685 | REC_0003894 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 20 | 5.2 | 47 | female | 0 | 12 | 5.6 | 5 | pembrolizumab 200 mg q3w | 9.8 | true | MSS | 2026-03-15T05:35:57.808178+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_205295 | REC_0003895 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 19 | 8 | 76 | male | 3 | 5 | 7.2 | 5 | pembrolizumab 200 mg q3w | 11.5 | true | MSS | 2026-03-15T05:35:57.808432+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_129796 | REC_0003896 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 22 | 12.6 | 63 | male | 0 | 15 | 5.7 | 7 | osimertinib 80 mg daily | 10.3 | true | MSI-H | 2026-03-15T05:35:57.808676+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_429813 | REC_0003897 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 30 | 13.9 | 69 | female | 0 | 21 | 5.8 | 1 | alectinib 600 mg BID | 13 | false | MSS | 2026-03-15T05:35:57.808910+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_587395 | REC_0003898 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 25 | 16.5 | 66 | male | 1 | 24 | 4 | 6 | sotorasib 960 mg daily | 11.1 | true | MSI-H | 2026-03-15T05:35:57.809144+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_975002 | REC_0003899 | Non-small cell lung cancer | Squamous cell carcinoma | III | None | 31 | 7.7 | 80 | male | 1 | 45 | 2.5 | 0 | carboplatin + paclitaxel + pembrolizumab | 38.3 | false | MSS | 2026-03-15T05:35:57.809374+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_390900 | REC_0003900 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 16 | 7.8 | 64 | female | 0 | 38 | 5.1 | 1 | carboplatin + paclitaxel + pembrolizumab | 17 | false | MSS | 2026-03-15T05:35:57.809606+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.